🔗 Share this article

Given that the United States proceeds with sweeping changes to its vaccine recommendations, a particular individual appears in a surprising turn: Høeg, a Danish American sports medicine doctor and epidemiologist who rose to prominence by casting doubt on COVID-19 shots in the global health crisis and has concentrated on possible deaths after Covid vaccination in her brief time at the Food and Drug Administration.

Scheduled Overhauls to Childhood Immunization Program

Public health authorities planned to announce major changes to the childhood immunization program in December, synchronizing the US with the Danish immunization schedule, it is understood – a major change that would place the US out of alignment with many the international standard with insufficient data for improved outcomes. The planned update has been pushed back until the coming year.

Instead of the top vaccines chief, Høeg is scheduled to speak at the meeting. She was just designated acting director of the FDA’s drug evaluation center, the fifth appointee to run the division this year.

Consolidating Power at the Regulatory Body

This interim role could signify a closer partnership between the pharmaceutical and biologics divisions as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for ending certain pediatric shot schedules in the US to become more in line with Denmark, a nation with comprehensive healthcare and a number of inhabitants roughly the population of Wisconsin’s.

In her initial public appearances, she has continued to focus on vaccines – usually the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than medication approval.

Concerns Over Background

The appointee has no apparent background in medication creation, oversight or leadership, which has been standard for previous heads of the biologics center. She has been employed at the FDA as a key advisor to the commissioner and CBER since earlier this year.

“She appears not to have the necessary background” for leading the drug-regulation department, said Jonathan Howard. “She’s never run a clinical trial. She lacks experience in managing a major agency. She lacks background in industry regulation.”

Past directors of the center would “grasp legal statutes and the research of medication creation”, said a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that previous people who headed the center have had.”

CDER has an vast range of responsibilities at the FDA, Woodcock pointed out.

“The public just zeroes in on the novel medication approvals, but the generic drug division clears numerous off-brand pharmaceuticals. There is also a biologic copycat branch, over-the-counter program and more, and every single one need to be supervised,” Dr. Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Furthermore, a significant leadership aspect to the job, which supervises in excess of 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official added.

Official Statement and Contentious Programs

When asked about concerns about Dr. Høeg's fitness for the role and whether this selection indicates increased cooperation among FDA leaders on immunizations, a spokesperson said that the “concerns rely on inaccurate premises”.

“This background matches the functions of her role,” the official stated, noting the time Høeg spent guiding the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's recently launched expedited review system, a controversial rapid medication authorization process that reportedly concerned her predecessors. “How are these medications being selected for this expedited pathway? Who makes the calls?” Howard questioned. “There’s a lot of lack of transparency going on at the FDA right now.”

In general, he remarked, “the agency looks to be trending towards more relaxed regulations of most medications, aside from vaccines.”

Public Past Work on Vaccines

Regarding vaccines, Dr. Høeg has a clearer, if concerning, past, Howard said. She published a research paper using unconfirmed public submissions to assess the incidence of myocarditis after Covid immunization. She counseled the Florida top health official Joseph Ladapo, who was said to have changed statistics to suggest COVID-19 vaccines are more dangerous than they are.

Among her “policy goals” for the new federal leadership featured revising regulations for recently developed shots and discontinuing “non-essential” vaccines, she stated after the election on a audio program. At the FDA, Dr. Høeg has allegedly proposed excluding young men from getting Covid vaccinations.

“She is an all-around true believer who commences with her preconceived notions and works backwards to accommodate the data in a very deceptive, dishonest fashion,” Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined other contrarians, {like|